Da Vinci Laboratory Solutions accelerates growth through acquisition of JSB
Amsterdam, April 10, 2024 –Our portfolio company Da Vinci Laboratory Solutions (Da Vinci) is acquiring industry peer JSB. Da Vinci and JSB are two well-established companies in the international analytical chemistry market with a focus on chromatography. With the unification of Da Vinci and JSB, Da Vinci strengthens its position as a leading player in the field of knowledge-intensive total solutions in chromatography in the Benelux and beyond.
Developer of specialized chromatography solutions
Da Vinci and JSB operate as suppliers of analytical systems to laboratories, specifically based on chromatography and mass spectrometry. Within these niche markets, Da Vinci and JSB are known as knowledge-intensive companies, delivering added value based on systems from the publicly traded American company Agilent Technologies. Specifically, Da Vinci and JSB integrate chromatography systems with in-house developed and third-party systems to provide a customized total solution to the customer. Around these custom-made chromatography systems, both companies provide consumables as well as technical maintenance and installation services.
Joining forces
The chromatography market is subject to growing customer demand for increasingly complex and sensitive measurements. This desire from customers requires continuous technological development and product knowledge from companies such as Da Vinci and JSB. The unification of Da Vinci and JSB brings together two complementary product and service portfolios, enabling the combination to meet this customer demand even better. The acquisition also strengthens Da Vinci’s international footprint with an office in the United Kingdom, in addition to already existing international offices in India, China and Singapore.
In his new role, Sander Affourtit, COO of JSB, will become the operational director of the merged value-added partners of Agilent: “This increase in scale provides synergy for both parties knowledge and expertise can be shared, thus generating additional strength. Since the product package is complementary, more high-end chromatographic solutions will also become available through the combination.”
Martijn van Raalte CEO Da Vinci, “This merger enables us to create synergies, offer more innovative solutions, provide broader services and better meet the specific needs of our customers in various sectors.”
Philip Wilms, Investment Director Holland Capital, “The acquisition of JSB is an important step in the inorganic growth trajectory of Da Vinci. The market in which both companies operate is international, and having combined the two leading Benelux players we now aim to also expand this acquisition path internationally.”
About JSB
Since 2002 JSB has been active on the Benelux market as a full knowledge partner in chromatographic and mass spectrometric solutions. JSB is one of Agilent’s larger partners in the Netherlands and adds value on the Agilent systems by integrating these systems with complementary modules (e.g., sample preparation and detection equipment) to provide a customized solution for customers. JSB has 19 employees and has offices in Lelystad, Eindhoven and in the UK.
About Da Vinci Laboratory Solutions
Da Vinci Laboratory Solutions was founded as a service provider within the laboratory industry in 2000. Since then Da Vinci has grown to become the versatile partner for laboratories by offering chromatographic solutions for all analytical challenges from sample preparation, analysis, reporting, data management, consumables and technical support. Like JSB, Da Vinci is a value-added reseller of Agilent Technology. Da Vinci has offices in Rotterdam (HQ), Geleen, India, China and Singapore. The company has 50 employees and offers an extensive application and test laboratory, training room and R&D facilities. Da Vinci’s mission is to increase laboratory efficiency with its chromatographic solutions.
About Holland Capital
Holland Capital has been investing responsibly and successfully in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and pursues an open, sustainable and professional relationship with the management teams of the companies in which it invests, with the common goal of achieving growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams it concentrates on the Healthcare, Technology and the recently added focus area Agrifood-Tech. It knows the dynamics and opportunities in these sectors and has a broad network. Holland Capital has been involved in Da Vinci as a shareholder since October 2022. She actively supports the organization in both the operational and strategic development of the company.
Investeerder Holland Venture trekt EUR 55 miljoen aan voor nieuw private equity fonds
Amsterdam, 13 december 2016 – Holland Venture is een nieuw private equity fonds gestart. Het kapitaal is bedoeld voor middelgrote Nederlandse ondernemingen die actief zijn in de sectoren Healthcare en Technology. De fundraising verliep voortvarend; binnen drie maanden...
Holland Venture raises 55 million for a new private equity fund
Amsterdam, 13th of December 2016 - Holland Venture has launched a new private equity fund. The capital is intended for small and medium-sized Dutch companies operating in the fields of Healthcare and Technology. The fundraising went expeditiously; the target amount of...
Holland Venture investeert in cloud en security specialist Avensus Nederland BV
Amsterdam, 28 november 2016 – Investeringsmaatschappij Holland Venture investeert in cloud en security specialist Avensus. De investering steunt Avensus om verdere groei binnen de financiële wereld en de zorgsector te realiseren en haar technologische expertise binnen...
Holland Venture invests in cloud & security specialist Avensus Netherlands BV
Amsterdam, November 28th, 2016 - Holland Venture invests in cloud and security specialist Avensus. The investment supports Avensus to achieve further growth in the financial and healthcare sector and to further develop its technological expertise in cloud and...
Dankzij investering in Prolira BV door Holland Venture en Health Innovations wordt snelle detectie van delirium (delier) mogelijk
27 SEPTEMBER 2016: Met een financiële injectie, kennis en een groot netwerk in de zorg helpen Holland Venture, Health Innovations en twee business angels om de Delirium Monitor van Prolira tot de nieuwe internationale gouden standaard voor detectie van delirium te...
Thanks to investment in Prolira BV, by Holland Venture and Health Innovations, early detection of delirium will be possible.
27 SEPTEMBER 2016: With a cash injection, knowledge and a large network in healthcare, Holland Venture, Health Innovations and two business angels are helping to make Prolira’s Delirium Monitor the new international standard for detection of delirium.Delirium, an...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl